Press Releases
- Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy11/28/2022
- Sarepta Therapeutics to Present at the Evercore ISI HealthCONx Conference11/23/2022
- Sarepta Therapeutics Announces Third Quarter 2022 Financial Results and Recent Corporate Developments11/02/2022
News Features
Media Library
Press Contact
Tracy Sorrentino
Executive Director, Public Relations
Sarepta Therapeutics, Inc.
[email protected]
617-274-4052